Nothing was found on your request

celgene corporation

Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs

Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs

Mark J. Alles, the chief executive officer of Celgene, at a conference in Beverly Hills, Calif., in May.
Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs

Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs

Mark J. Alles, the chief executive officer of Celgene, at a conference in Beverly Hills, Calif., in May.
Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs

Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs

Mark J. Alles, the chief executive officer of Celgene, at a conference in Beverly Hills, Calif., in May.

Former Celgene CEO Bob Hugin to Challenge Sen. Bob Menendez

Bob Menendez dodged federal corruption charges, but the former drug company CEO is still jumping into the race.
A G.O.P. Senate Candidate Highlights His Drug Industry Career. Should He?

A G.O.P. Senate Candidate Highlights His Drug Industry Career. Should He?

Bob Hugin spoke in 2014 at a groundbreaking ceremony in Summit, N.J., for Celgene, the pharmaceutical company he led until stepping down to run for United States Senate. To his right are
A G.O.P. Senate Candidate Highlights His Drug Industry Career. Should He?

A G.O.P. Senate Candidate Highlights His Drug Industry Career. Should He?

Bob Hugin spoke in 2014 at a groundbreaking ceremony in Summit, N.J., for Celgene, the pharmaceutical company he led until stepping down to run for United States Senate. To his right are
Bristol-Myers to Acquire Celgene in Deal Worth $74 Billion

Bristol-Myers to Acquire Celgene in Deal Worth $74 Billion

After the deal is completed, expected this year, Bristol-Myers Squibb shareholders will own 69 percent of the combined entity, while Celgene shareholders will own 31 percent.
Bristol-Myers to Acquire Celgene in Deal Worth $74 Billion

Bristol-Myers to Acquire Celgene in Deal Worth $74 Billion

After the deal is completed, expected this year, Bristol-Myers Squibb shareholders will own 69 percent of the combined entity, while Celgene shareholders will own 31 percent.
Bristol-Myers to Acquire Celgene in Deal Worth $74 Billion

Bristol-Myers to Acquire Celgene in Deal Worth $74 Billion

After the deal is completed, expected this year, Bristol-Myers Squibb shareholders will own 69 percent of the combined entity, while Celgene shareholders will own 31 percent.

Big Pharma’s Hunt for New Drugs Is Pushing Up Cost of Deals

Just two months into the year, the value of acquisitions of American biotech companies has already exceeded last year’s total.

Drugmaker Deals Are Near Record Pace in 2019, but Investors Don’t Love Them All

A rush of transactions is transforming the industry, as blockbuster medicines lose patent protection. The latest acquisition cost AbbVie 16 percent of its share price.